HOUSTON, Nov. 7, 2022
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX)
("Moleculin" or the "Company"), a clinical stage pharmaceutical
company with a broad portfolio of drug candidates targeting highly
resistant tumors and viruses, today announced that it will report
its financial results for the quarter ended September 30, 2022 on Thursday, November 10th. Moleculin
management will host its inaugural quarterly conference call and
live audio webcast to discuss the operational and financial results
at 5:00 PM ET that same
day.
The call will be led by Walter
Klemp, Chairman and Chief Executive Officer of Moleculin and
Jonathan Foster, Executive VP &
Chief Financial Officer of Moleculin. Interested participants and
investors may access the conference call by dialing (877) 407-0832
(domestic) or (201) 689-8433 (international) and referencing the
Moleculin Biotech Conference Call. The live webcast will be
accessible on the Events page of the Investors section of the
Moleculin website, moleculin.com, and will be archived for 90
days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of drug
candidates for the treatment of highly resistant tumors and
viruses. The Company's lead program, Annamycin is a next-generation
anthracycline designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity. Annamycin is currently in
development for the treatment of relapsed or refractory acute
myeloid leukemia (AML) and soft tissue sarcoma (STS) lung
metastases.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in the development of a portfolio of antimetabolites, including
WP1122 for the potential treatment of COVID-19 and other viruses,
as well as cancer indications including brain tumors, pancreatic
and other cancers.
For more information about the Company, please visit
www.moleculin.com and connect on Twitter, LinkedIn and
Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-to-report-third-quarter-2022-financial-results-on-november-10-2022-and-host-inaugural-quarterly-conference-call-and-webcast-301669648.html
SOURCE Moleculin Biotech, Inc.